![]() ![]() In his newsletter, attorney and former Oregon Psilocybin Advisory Board member Mason Marks explains that the advisory board debated including data collection provisions in the Oregon Psilocybin Services’ final rules, but ultimately decided not to. In early January, we reported on Oregon’s Senate Bill 303, which would mandate that the Oregon Health Authority require all psilocybin service centers and facilitators to collect and report data about clients, including demographic information and their treatment details. Measure 109 officially took effect at the beginning of this year, and now the hard work of implementing that legislation begins. The Latest in Oregon: Contentious new legislation That subcommittee voted 5-2 against the bill last week, according to the AP. Two weeks ago, we reported on Virginia’s HB 1513, which would allow psilocybin to be used to treat depression, PTSD, and end-of-life anxiety the bill was referred to the House Courts of Justice subcommittee. In addition, the bill stipulates that patients participating in such studies would not face legal prosecution. The bill would also require researchers to register any studies using psilocybin with the State Department of Health and the Oklahoma Department of Agriculture, Food, and Forestry. The bill also would establish an advisory committee to make recommendations about how such therapy would be delivered.Īnd Oklahoma representative Daniel Pae (R) introduced House Bill 2107, which explicitly states that researchers in the state would not face legal prosecution for conducting studies and clinical trials using psilocybin to treat conditions like PTSD, depression, traumatic brain injury, chronic pain, and opioid use disorder, among others. In Missouri, representative Tony Lovasco (R) introduced House Bill 869 last week, which would allow people over 21 with treatment-resistant depression, PTSD, or a terminal illness to receive psilocybin therapy. The text for both bills is identical filing in both chambers is “a signal to the committee it will be assigned to that this bill is a priority and a big deal,” James Davis, a legislative director working with BSNM, told The Microdose. Last week, state representative Lindsay Sabadosa (D) introduced HD.1450 in the House while senator Patricia Jehlen (D) introduced SD.949 in the Senate. The community group Bay Staters for Natural Medicine (BSNM) partnered with Massachusetts legislators to draft legislation to decriminalize the possession, ingestion, obtaining, growing, giving away, and transportation of less than two grams of psilocybin, psilocin, DMT, ibogaine, and mescaline. The State of Psychedelics: New bills in Massachusetts, Missouri, Oklahoma ![]() ![]() “Given their shared mechanism of 5-HT 2A agonism or partial agonism, we suspect that this is either the direct or indirect cause of menstrual changes and that these effects likely occur somewhere along the hypothalamic-pituitary-gonadal axis.” It may be that these cases are rare, but further research is warranted, especially as more people who menstruate seek psychedelic treatment. “Taken together, these cases suggest that a variety of classic psychedelics including LSD, psilocybin, ayahuasca, and mescaline may all produce striking changes in menstrual function,” Gukasyan and Narayan write. These findings echo those from a series of reports published in a 1957 paper published in the Spanish-language journal La Semana medica. ![]()
0 Comments
Leave a Reply. |